Dapagliflozin + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Heart Failure，Congestive
Conditions
Heart Failure，Congestive
Trial Timeline
Feb 15, 2021 → Oct 28, 2024
NCT ID
NCT04869124About Dapagliflozin + Placebo
Dapagliflozin + Placebo is a approved stage product being developed by AstraZeneca for Heart Failure，Congestive. The current trial status is completed. This product is registered under clinical trial identifier NCT04869124. Target conditions include Heart Failure，Congestive.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04792190 | Approved | Completed |
| NCT04869124 | Approved | Completed |
| NCT04564742 | Phase 3 | Completed |
| NCT04363697 | Approved | Completed |
| NCT04475042 | Phase 2 | UNKNOWN |
| NCT02981966 | Approved | Completed |
| NCT03619213 | Phase 3 | Completed |
| NCT03387683 | Approved | Completed |
| NCT02956811 | Approved | Completed |
| NCT03036124 | Phase 3 | Completed |
| NCT03036150 | Phase 3 | Completed |
| NCT02796170 | Approved | Completed |
| NCT02520518 | Phase 2 | Terminated |
| NCT02459353 | Approved | Completed |
| NCT02371187 | Phase 2 | Completed |
| NCT02426541 | Approved | Completed |
| NCT01392677 | Phase 3 | Completed |
| NCT01042977 | Phase 3 | Completed |
| NCT01031680 | Phase 3 | Completed |
| NCT00984867 | Phase 3 | Completed |
Competing Products
20 competing products in Heart Failure，Congestive
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IV diuretic | Nuwellis | Pre-clinical | 15 |
| IV Loop Diuretics | Nuwellis | Pre-clinical | 15 |
| Stepped pharmacologic care | Nuwellis | Phase 3 | 69 |
| IV Loop Diuretics (LD) | Nuwellis | Pre-clinical | 15 |
| TRV120027 + Normal Saline | Trevena | Phase 1 | 25 |
| TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo | Trevena | Phase 2 | 44 |
| TRV120027 + Placebo | Trevena | Phase 1/2 | 33 |
| Ilofotase alfa + Placebo | AM-Pharma | Phase 2 | 44 |
| INXN-4001 | Precigen | Phase 1 | 28 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 33 |
| SGLT2i, beta blocker, ARNI, MRA, MTD | Eli Lilly | Approved | 85 |
| Pactimibe, CS-505 | Daiichi Sankyo | Phase 2 | 52 |
| Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks | Daiichi Sankyo | Approved | 85 |
| olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetil | Daiichi Sankyo | Phase 3 | 77 |
| Olmesartan | Daiichi Sankyo | Phase 3 | 77 |
| Carperitide + Placebo | Daiichi Sankyo | Phase 2 | 52 |
| Edoxaban | Daiichi Sankyo | Pre-clinical | 23 |
| Regadenoson | Astellas Pharma | Phase 1 | 33 |
| Advagraf + Prograf | Astellas Pharma | Phase 2 | 52 |
| FK506E | Astellas Pharma | Phase 3 | 77 |